JAGX
Price
$0.48Alerts
Change
+$0.04 (+9.09%)
Updated
Nov 11 closing price
Capitalization
210.27K
2 days until earnings call
Intraday BUY SELL Signals
SPRO
Price
$1.02Alerts
Change
+$0.01 (+0.99%)
Updated
Nov 11 closing price
Capitalization
59.98M
One day until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

JAGX vs SPRO

JAGX vs SPRO Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
JAGX vs. SPRO commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JAGX is a Hold and SPRO is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for JAGX with price predictions
Nov 10, 2026

Momentum Indicator for JAGX turns negative, indicating new downward trend

JAGX saw its Momentum Indicator move below the 0 level on October 16, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 67 similar instances where the indicator turned negative. In 65 of the 67 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where JAGX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for JAGX entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for JAGX just turned positive on November 06, 2026. Looking at past instances where JAGX's MACD turned positive, the stock continued to rise in 33 of 40 cases over the following month. The odds of a continued upward trend are 82%.

Following a +8.01% 3-day Advance, the price is estimated to grow further. Considering data from situations where JAGX advanced for three days, in 137 of 171 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

JAGX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 46 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.032) is normal, around the industry mean (3.498). P/E Ratio (0.000) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.003) is also within normal values, averaging (440.869).

The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 99 (best 1 - 100 worst), indicating slightly worse than average price growth. JAGX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. JAGX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for SPRO with price predictions
Nov 10, 2026

SPRO sees its Stochastic Oscillator recovers from oversold territory

On November 09, 2026, the Stochastic Oscillator for SPRO moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 69 instances where the indicator left the oversold zone. In 56 of the 69 cases the stock moved higher in the following days. This puts the odds of a move higher at over 81%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a +4.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where SPRO advanced for three days, in 152 of 209 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SPRO as a result. In 78 of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

The Moving Average Convergence Divergence Histogram (MACD) for SPRO turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 33 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.

SPRO moved below its 50-day moving average on October 21, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for SPRO crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 80%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SPRO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

The Aroon Indicator for SPRO entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 48 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 78 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.357) is normal, around the industry mean (3.498). P/E Ratio (7.357) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1.550) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 79 (best 1 - 100 worst), indicating slightly worse than average price growth. SPRO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 91 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SPRO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

FUNDAMENTALS RATINGS
JAGX vs SPRO: Fundamental Ratings
JAGX
SPRO
OUTLOOK RATING
1..100
667
VALUATION
overvalued / fair valued / undervalued
1..100
46
Fair valued
78
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10048
PRICE GROWTH RATING
1..100
9979
P/E GROWTH RATING
1..100
9791
SEASONALITY SCORE
1..100
35n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

JAGX's Valuation (46) in the Pharmaceuticals Generic industry is in the same range as SPRO (78) in the Pharmaceuticals Major industry. This means that JAGX’s stock grew similarly to SPRO’s over the last 12 months.

JAGX's Profit vs Risk Rating (100) in the Pharmaceuticals Generic industry is in the same range as SPRO (100) in the Pharmaceuticals Major industry. This means that JAGX’s stock grew similarly to SPRO’s over the last 12 months.

SPRO's SMR Rating (48) in the Pharmaceuticals Major industry is somewhat better than the same rating for JAGX (100) in the Pharmaceuticals Generic industry. This means that SPRO’s stock grew somewhat faster than JAGX’s over the last 12 months.

SPRO's Price Growth Rating (79) in the Pharmaceuticals Major industry is in the same range as JAGX (99) in the Pharmaceuticals Generic industry. This means that SPRO’s stock grew similarly to JAGX’s over the last 12 months.

SPRO's P/E Growth Rating (91) in the Pharmaceuticals Major industry is in the same range as JAGX (97) in the Pharmaceuticals Generic industry. This means that SPRO’s stock grew similarly to JAGX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
JAGXSPRO
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
N/A
Bullish Trend 2 days ago
81%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
82%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
86%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 3 days ago
73%
Declines
ODDS (%)
Bearish Trend 6 days ago
90%
Bearish Trend 10 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
89%
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
87%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (JAGX: $0.44 vs. SPRO: $1.01)
Brand notoriety: JAGX and SPRO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: JAGX: 22% vs. SPRO: 33%
Market capitalization -- JAGX: $210.27K vs. SPRO: $59.98M
JAGX [@Biotechnology] is valued at $210.27K. SPRO’s [@Biotechnology] market capitalization is $59.98M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

JAGX’s FA Score shows that 0 FA rating(s) are green while SPRO’s FA Score has 0 green FA rating(s).

  • JAGX’s FA Score: 0 green, 5 red.
  • SPRO’s FA Score: 0 green, 5 red.
According to our system of comparison, both JAGX and SPRO are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

JAGX’s TA Score shows that 3 TA indicator(s) are bullish while SPRO’s TA Score has 2 bullish TA indicator(s).

  • JAGX’s TA Score: 3 bullish, 3 bearish.
  • SPRO’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, JAGX is a better buy in the short-term than SPRO.

Price Growth

JAGX (@Biotechnology) experienced а -21.67% price change this week, while SPRO (@Biotechnology) price change was -2.88% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.

Reported Earning Dates

JAGX is expected to report earnings on Nov 13, 2026.

SPRO is expected to report earnings on Nov 12, 2026.

Industries' Descriptions

@Biotechnology (+4.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

JAGX and

Correlation & Price change

A.I.dvisor indicates that over the last year, JAGX has been loosely correlated with VKTX. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if JAGX jumps, then VKTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To JAGX
1D Price
Change %
JAGX100%
+0.14%
VKTX - JAGX
45%
Loosely correlated
-1.14%
FLNA - JAGX
43%
Loosely correlated
-2.03%
TCRT - JAGX
36%
Loosely correlated
+2.40%
MNOV - JAGX
35%
Loosely correlated
-4.76%
SPRO - JAGX
33%
Loosely correlated
-5.61%
More

SPRO and

Correlation & Price change

A.I.dvisor indicates that over the last year, SPRO has been loosely correlated with CCXI. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if SPRO jumps, then CCXI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SPRO
1D Price
Change %
SPRO100%
-5.61%
CCXI - SPRO
48%
Loosely correlated
N/A
ASBP - SPRO
42%
Loosely correlated
+0.06%
VYGR - SPRO
36%
Loosely correlated
-8.29%
JAGX - SPRO
33%
Loosely correlated
+0.14%
FLNA - SPRO
33%
Loosely correlated
-2.03%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
FINY25.250.07
+0.28%
GraniteShares YieldBOOST Financials ETF (FINY)
XIDE30.24N/A
N/A
FT Vest U.S. Equity Buffer & Premium Income ETF - December (XIDE)
EOS20.11-0.03
-0.15%
Eaton Vance Enhance Equity Income Fund II
BSMU21.60-0.05
-0.21%
Invesco BulletShares 2030 Municipal Bond ETF (BSMU)
ITDB34.74-0.20
-0.57%
iShares LifePath Target Date 2030 ETF (ITDB)